Neoplasms

All Conditions

Digestive System Diseases

Gland and Hormone Related Diseases

Rare Diseases

Carcinoma

Adenocarcinoma

Pancreatic Neoplasms

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Gastrointestinal Neoplasms

Digestive System Neoplasms

Endocrine Gland Neoplasms

Gastrointestinal Diseases

Pancreatic Diseases

Endocrine System Diseases

Pancreatic Cancer

Individuals diagnosed with pancreatic ductal adenocarcinoma

Individuals without pancreatic ductal adenocarcinoma

This test will utilize quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) to quantify the expression levels of 5 cell-free and 8 exosome-miRNAs in plasma samples obtained from patients with pancreatic ductal adenocarcinoma and from individuals without it

PANcreatic cancer Exosome Early detectiON (PANXEON)

Ajay Goel, PhD

Daniel Von Hoff

Haiyong Han

Derek Cridebring

Erkut Borazanci

Ajay Goel

Stanley Hamilton

Vincent Chung

Caiming Xu

Alessandro Mannucci

Michael Demeure

Chandler Wilfong

John Bolton

Angela Alistar

Eric Whitman

Andrew Page

Eyal Meiri

Douglas Evans

Yasuhiro Kodera

Masamichi Hayashi

Song Cheol Kim

This study aims to prospective validate an exosome-based miRNA signature for noninvasive and early detection of pancreatic ductal adenocarcinoma.

Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest forms of cancer. It often goes undetected until it is at an advanced stage, making it challenging to treat. Currently, only a small percentage of patients are diagnosed early enough for effective treatment. While a blood marker exists, called serum carbohydrate antigen 19-9 (CA19-9), it is used primarily to track the disease and it is unreliable for early detection.

To address this problem, the researchers have developed a new method to analyze circulating vesicles (called exosomes), which contain specific genetic material called microRNAs (miRNAs). In a previous study, by analyzing both the miRNAs that circulate freely in serum and the miRNAs that are inside the exosomes, the researchers have already identified a combination of 13 miRNAs that could accurately detect early-stage PDAC.

In this study, the researchers will test this method in a larger international cohort study. This study aims to confirm the effectiveness of this approach in accurately identifying PDAC at its earliest stages.

Pancreatic Cancer Detection Consortium

Early Detection of Pancreatic Cancer: Prospective Study

Data collected for the study will be made available to others, including de-identified participant data, at publication, via a signed data access agreement and at the discretion of the investigators' approval of the proposed use of such data

True positive rate: the probability of a positive test result, conditioned on the individual truly being positive

True negative rate: the probability of a negative test result, conditioned on the individual truly being negative

A measure of trueness: proportion of correct predictions (both true positives and true negatives) among the total number of cases examined

City of Hope Medical Center

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Pancreatic Cancer Detection Consortium	NCT06388967	Pancreatic Canc... Pancreatic Carc... Pancreatic Aden... Pancreatic Duct... Pancreatic Neop... Pancreatic Canc... Pancreatic Canc... Pancreatic Canc... Pancreatic Canc... Pancreatic Canc... Pancreatic Canc... Pancreatic Canc... Pancreatic Canc...	PANcreatic canc...	18 Years -	City of Hope Medical Center
Pancreatic Cancer Detection Consortium	NCT06388967	Pancreatic Canc... Pancreatic Carc... Pancreatic Aden... Pancreatic Duct... Pancreatic Neop... Pancreatic Canc... Pancreatic Canc... Pancreatic Canc... Pancreatic Canc... Pancreatic Canc... Pancreatic Canc... Pancreatic Canc... Pancreatic Canc...	PANcreatic canc...	18 Years -	City of Hope Medical Center

Spots Global Cancer Trial Database for pancreatic cancer exosome early detection (panxeon)